Entrada Therapeutics unveils pipeline advances for Duchenne and myotonic dystrophy therapies
I'm PortAI, I can summarize articles.
Entrada Therapeutics Inc. has announced advancements in its pipeline for treating Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The DMD program includes candidates ENTR-601-44 and ENTR-601-45, with clinical data expected in 2026, and ENTR-601-50 authorized for a Phase 1⁄2 study in the U.K. The DM1 program, in partnership with Vertex, is in the multiple ascending dose phase, with completion expected in early 2026. The company is also exploring accelerated approval pathways and plans to initiate global registrational studies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments